GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaTher Holdings Ltd (XCNQ:PHRM) » Definitions » Notes Receivable

PharmaTher Holdings (XCNQ:PHRM) Notes Receivable : C$0.00 Mil (As of Feb. 2024)


View and export this data going back to 2021. Start your Free Trial

What is PharmaTher Holdings Notes Receivable?

PharmaTher Holdings's Notes Receivable for the quarter that ended in Feb. 2024 was C$0.00 Mil.


PharmaTher Holdings Notes Receivable Historical Data

The historical data trend for PharmaTher Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaTher Holdings Notes Receivable Chart

PharmaTher Holdings Annual Data
Trend May21 May22 May23
Notes Receivable
- - -

PharmaTher Holdings Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PharmaTher Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


PharmaTher Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of PharmaTher Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaTher Holdings (XCNQ:PHRM) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.
Executives
Fabio Chianelli Director, Senior Officer

PharmaTher Holdings (XCNQ:PHRM) Headlines

No Headlines